MARKET

CMRX

CMRX

Chimerix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.77
-0.03
-0.44%
Opening 11:16 09/23 EDT
OPEN
6.80
PREV CLOSE
6.80
HIGH
6.86
LOW
6.68
VOLUME
149.32K
TURNOVER
--
52 WEEK HIGH
11.57
52 WEEK LOW
2.430
MARKET CAP
583.91M
P/E (TTM)
-3.7819
1D
5D
1M
3M
1Y
5Y
Insider Sell: Chimerix
MT Newswires · 6d ago
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial a...
GlobeNewswire · 09/07 11:00
Return on Capital Employed Insights for Chimerix
After pulling data from Benzinga Pro it seems like during Q2, Chimerix's (NASDAQ:CMRX) reported sales totaled $391.00 thousand. Despite a 81.72% in earnings, the company posted a loss of $17.82 million.
Benzinga · 08/27 21:14
Did You Miss Chimerix's (NASDAQ:CMRX) Impressive 108% Share Price Gain?
Chimerix, Inc. ( NASDAQ:CMRX ) shareholders might be concerned after seeing the share price drop 17% in the last...
Simply Wall St. · 08/06 06:18
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
Chimerix EPS misses by $0.02, beats on revenue
Chimerix (NASDAQ:CMRX): Q2 GAAP EPS of -$0.21 misses by $0.02. Revenue of $0.39M (-72.1% Y/Y) beats by $0.09M. Press Release
Seekingalpha · 08/05 11:10
Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update
– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter...
GlobeNewswire · 08/05 11:00
-- Earnings Flash (CMRX) CHIMERIX Reports Q2 Revenue $391,000, vs. Street Est of $0.3M
MT Newswires · 08/05 07:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMRX. Analyze the recent business situations of Chimerix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CMRX stock price target is 17.67 with a high estimate of 20.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 150
Institutional Holdings: 55.85M
% Owned: 64.76%
Shares Outstanding: 86.25M
TypeInstitutionsShares
Increased
38
3.52M
New
26
1.58M
Decreased
32
3.53M
Sold Out
15
4.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.90%
Pharmaceuticals & Medical Research
+1.17%
Key Executives
Non-Executive Chairman/Independent Director
Martha Demski
President/Chief Executive Officer/Director
Michael Sherman
Chief Financial Officer
Michael Andriole
Other
Allen Melemed
Independent Director
Catherine Gilliss
Independent Director
Patrick Machado
Independent Director
Robert Meyer
Independent Director
Fred Middleton
Independent Director
Pratik Multani
Independent Director
Vicki Vakiener
No Data
About CMRX
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.

Webull offers kinds of Chimerix Inc stock information, including NASDAQ:CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.